{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:45:00Z","timestamp":1762163100141,"version":"build-2065373602"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01820-9","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:38:21Z","timestamp":1762162701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NPRL2 gene expression as a predictor of biochemical recurrence after robot-assisted radical prostatectomy"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-3697","authenticated-orcid":false,"given":"Sedat","family":"Yahsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0334-2076","authenticated-orcid":false,"given":"P\u0131nar","family":"\u00d6ks\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-383X","authenticated-orcid":false,"given":"Kaz\u0131m","family":"Ceviz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-1291","authenticated-orcid":false,"given":"Cavit","family":"Ceylan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"1820_CR1","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/j.1464-410X.2010.09833.x","volume":"107","author":"CN Anandadas","year":"2011","unstructured":"Anandadas CN, Clarke NW, Davidson SE, O\u2019Reilly PH, Logue JP, Gilmore L, et al. Early prostate cancer\u2013which treatment do men prefer and why? BJU Int. 2011;107:1762\u20138.","journal-title":"BJU Int"},{"key":"1820_CR2","doi-asserted-by":"crossref","unstructured":"Falagario UG, Knipper S, Pellegrino F, Martini A, Akre O, Egevad L, Gr\u00f6nberg H, Moschovas MC, Bravi CA, Tran J, Heiniger Y, von Kempis A, Schaffar R, Carrieri G, Rochat CH, Mottrie A, Ahlering TE, John H, Patel V, Graefen M, Wiklund P. ERUS scientific working group on prostate Cancer of the European association of urology: prostate cancer-specific and all-cause mortality after robot-assisted radical prostatectomy: 20 years\u2019 report from the European association of urology robotic urology section scientific working group. Eur Urol Oncol; 2023.","DOI":"10.1016\/S2666-1683(23)00443-3"},{"key":"1820_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","volume":"44","author":"R Tourinho-Barbosa","year":"2018","unstructured":"Tourinho-Barbosa R, Srougi V, Nunes- Silva I, Baghdadi M, Rembeyo G, Eiffel SS, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol. 2018;44:14\u201321.","journal-title":"Int Braz J Urol"},{"key":"1820_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/jmri.26928","volume":"51","author":"I Jambor","year":"2020","unstructured":"Jambor I, Falagario U, Ratnani P, Perez IM, Demir K, Merisaari H, et al. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and Decipher genomic score. J Magn Reson Imaging. 2020;51:1075\u201385.","journal-title":"J Magn Reson Imaging"},{"key":"1820_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000481438","volume":"100","author":"W Artibani","year":"2018","unstructured":"Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of biochemical recurrence after primary curative treatment for prostate cancer: A review. Urol Int. 2018;100:251\u201362.","journal-title":"Urol Int"},{"issue":"1","key":"1820_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.juro.2016.07.004","volume":"197","author":"L Liesenfeld","year":"2017","unstructured":"Liesenfeld L, Kron M, Gschwend JE, Herkommer K. Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy. J Urol. 2017;197(1):143\u20138.","journal-title":"J Urol"},{"key":"1820_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"1820_CR8","doi-asserted-by":"publisher","first-page":"26259","DOI":"10.18632\/oncotarget.8456","volume":"7","author":"S Kregel","year":"2016","unstructured":"Kregel S, Chen JL, Tom W, et al. Acquired resistance to the second- generation androgen receptor antagonist enzalutamide in castration- resistant prostate cancer. Oncotarget. 2016;7:26259\u201374.","journal-title":"Oncotarget"},{"key":"1820_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162:454.","journal-title":"Cell"},{"issue":"2","key":"1820_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/0008-5472.CAN-14-2315","volume":"75","author":"Y Peng","year":"2015","unstructured":"Peng Y, Dai H, Wang E, Lin CC, Mo W, Peng G, Lin SY. TUSC4 functions as a tumor suppressor by regulating BRCA1 stability. Cancer Res. 2015;75(2):378\u201386.","journal-title":"Cancer Res"},{"issue":"12","key":"1820_CR11","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/hep4.2019","volume":"6","author":"YC Wang","year":"2022","unstructured":"Wang YC, Tsai MC, Chen YS, Hsieh PM, Hung CM, Lin HY, et al. NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. Hepatol Commun. 2022;6(12):3563\u201377.","journal-title":"Hepatol Commun"},{"issue":"11","key":"1820_CR12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/mc.22413","volume":"55","author":"N Huang","year":"2016","unstructured":"Huang N, Cheng S, Mi X, Tian Q, Huang Q, Wang F, et al. Downregulation of nitrogen permease regulator like-2 activates PDK1-AKT1 and contributes to the malignant growth of glioma cells. Mol Carcinog. 2016;55(11):1613\u201326.","journal-title":"Mol Carcinog"},{"key":"1820_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s12253-014-9761-2","volume":"20","author":"Y Tang","year":"2014","unstructured":"Tang Y, Jiang L, Tang W. Decreased expression of NPRL2 in renal can- Cer cells is associated with unfavourable pathological, proliferation and apoptotic features. Pathol Oncol Res. 2014;20:829\u201337.","journal-title":"Pathol Oncol Res"},{"key":"1820_CR14","doi-asserted-by":"publisher","first-page":"9682","DOI":"10.1158\/0008-5472.CAN-06-1483","volume":"66","author":"K Ueda","year":"2006","unstructured":"Ueda K, Kawashima H, Ohtani S, et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non\u2013small-cell lung cancer cells. Cancer Res. 2006;66:9682\u201390.","journal-title":"Cancer Res"},{"key":"1820_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled L, Chantranupong L, Cherniack AD, et al. A tumor suppressor complex with GAP activity for the rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013;340:1100\u20136.","journal-title":"Science"},{"key":"1820_CR16","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grad- ing of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244\u2013\u200952.","DOI":"10.1097\/PAS.0000000000000530"},{"issue":"1","key":"1820_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12885-017-3439-6","volume":"17","author":"T Fujimura","year":"2017","unstructured":"Fujimura T, Fukuhara H, Taguchi S, Yamada Y, Sugihara T, Nakagawa T, Niimi A, Kume H, Igawa Y, Homma Y. Robot- assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy. BMC Cancer. 2017;17(1):454.","journal-title":"BMC Cancer"},{"issue":"4","key":"1820_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.56434\/j.arch.esp.urol.20227504.46","volume":"75","author":"S Yah\u015fi","year":"2022","unstructured":"Yah\u015fi S, Ceylan C, Kizilkan Y, \u015eenel S, Ceviz K. Cribriform morphology in Gleason score 3\u2009+\u20094 Moderate-Risk prostate cancer: is it risk factor for biochemical recurrence?? Arch Esp Urol. 2022;75(4):325\u20139.","journal-title":"Arch Esp Urol"},{"key":"1820_CR19","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00432-017-2502-7","volume":"143","author":"W Song","year":"2017","unstructured":"Song W, Lee DH, Jeon HG, et al. Impact of Gleason score on biochemical recurrence in patients with pT3aN0\/Nx prostate cancer with positive surgical margins: a multicenter study from the prostate Cancer research committee. J Cancer Res Clin Oncol. 2017;143:2393\u2013400.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1820_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1464-410X.2010.09539.x","volume":"107","author":"BA O\u2019Brien","year":"2011","unstructured":"O\u2019Brien BA, Cohen RJ, Wheeler TM, Moorin RE. A post- radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis. BJU Int. 2011;107:389\u201395.","journal-title":"BJU Int"},{"key":"1820_CR21","unstructured":"EAU Prostate Cancer Chapter. Available at https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"issue":"2","key":"1820_CR22","doi-asserted-by":"publisher","first-page":"111981","DOI":"10.1016\/j.yexcr.2020.111981","volume":"390","author":"S Luo","year":"2020","unstructured":"Luo S, Shao L, Chen Z, Hu D, Jiang L, Tang W. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway. Exp Cell Res. 2020;390(2):111981.","journal-title":"Exp Cell Res"},{"key":"1820_CR23","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.4161\/auto.29397","volume":"10","author":"S Kira","year":"2014","unstructured":"Kira S, Tabata K, Shirahama-Noda K, et al. Reciprocal conversion of Gtr1 and Gtr2 nucleotide-binding States by Npr2-Npr3 inactivates TORC1 and induces autophagy. Autophagy. 2014;10:1565\u201378.","journal-title":"Autophagy"},{"issue":"2","key":"1820_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.bbrc.2018.11.062","volume":"508","author":"X Chen","year":"2019","unstructured":"Chen X, Chen Z, Zheng B, Tang W. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer. Biochem Biophys Res Commun. 2019;508(2):620\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"1820_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.humpath.2018.02.011","volume":"76","author":"Z Chen","year":"2018","unstructured":"Chen Z, Luo S, Chen Y, Xie X, Du Z, Jiang L. High expression of NPRL2 is linked to poor prognosis in patients with prostate cancer. Hum Pathol. 2018;76:141\u20138.","journal-title":"Hum Pathol"},{"issue":"9","key":"1820_CR26","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1007\/s00345-021-03661-1","volume":"39","author":"C White","year":"2021","unstructured":"White C, Staff I, McLaughlin T, Tortora J, Pinto K, Gangakhedkar A, Champagne A, Wagner J. Does post prostatectomy Decipher score predict biochemical recurrence and impact care? World J Urol. 2021;39(9):3281\u20136.","journal-title":"World J Urol"},{"issue":"5","key":"1820_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.23736\/S2724-6051.23.05395-8","volume":"75","author":"PJ Treacy","year":"2023","unstructured":"Treacy PJ, Falagario UG, Magniez F, Ratnani P, Wajswol E, Martini A, Jambor I, Wiklund P, Bentellis I, Barthe F, Kyprianou N, Durand M, Steffens D, Karunaratne S, Leslie S, Thanigasalam R, Tewari A. Decipher score predicts prostate specific antigen persistence after prostatectomy. Minerva Urol Nephrol. 2023;75(5):583\u201390.","journal-title":"Minerva Urol Nephrol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01820-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:38:22Z","timestamp":1762162702000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01820-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"type":"electronic","value":"1471-2490"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted by the Declaration of Helsinki (as revised in 2013). The present study protocol was reviewed and approved by the Institutional Review Board of Ankara City Hospital (approval number: E2-22-1194). As a retrospective analysis, a waiver of informed consent was granted by the institutional review board of Ankara City Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}